 The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children. Participants 4-18 years of age will be randomly assigned to either 5mgkg or 10mgkg dose of infliximab to be administered by intravenous infusion at four week intervals. Participant responses will be measured at at four to eight week intervals for up to ten months. 